A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome
A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome
复制标题
DOI：
10.1053/j.gastro.2008.02.014
复制
发表时间：
2008-05-01
期刊：
影响因子：
29.4
通讯作者：
Teuber, Peter
中科院分区：
文献类型：
--
作者：
Sanyal, Arun J.;Boyer, Thomas;Teuber, Peter
背景与目的：1 型肝肾综合征 (HRS) 是晚期肝病患者的进行性功能性肾衰竭。本研究的目的是评估特利加压素（一种全身动脉血管收缩剂）治疗 1 型肝硬化 HRS 的有效性和安全性。方法：进行了一项特利加压素的前瞻性、随机、双盲、安慰剂对照临床试验。两组 1 型 HRS 受试者均随机接受特利加压素（每 6 小时静脉注射 1 毫克）或安慰剂加白蛋白。如果血清肌酐 (SCr) 水平未下降基线的 30%，则收盘价将在第 4 天翻倍。治疗持续至第14天，除非发生治疗成功、死亡、透析或移植。治疗成功的定义是 SCr 水平降低至
Background & Aims: Hepatorenal syndrome (HRS) type 1 is a progressive functional renal failure in subjects with advanced liver disease. The aim of this study was to evaluate the efficacy and safety of terlipressin, a systemic arterial vasoconstrictor, for cirrhosis type 1 HRS. Methods: A prospective, randomized, double-blind, placebo-controlled clinical trial of terlipressin was performed. Subjects with type 1 HRS were randomized to terlipressin (1 mg intravenously every 6 hours) or placebo plus albumin in both groups. The close was doubled on day 4 if the serum creatinine (SCr) level did not decrease by 30% of baseline. Treatment was continued to day 14 unless treatment success, death, dialysis, or tran plantation occurred. Treatment success was defined by a decrease in SCr level to